ADSX Applied Digital Solutions (MM)

Former Medtronic Executive Joins RFID Company for People DELRAY BEACH, Fla., Feb. 13 /PRNewswire-FirstCall/ -- VeriChip Corporation (NASDAQ:CHIP), a provider of RFID systems for people in the healthcare industry, announced today that Michael Barbe has joined the Company as Vice President of Sales and Distribution for the VeriMed Patient Identification System. In this newly created position, Barbe will be responsible for marketing and sales of the VeriMed Patient Identification System and the development of the company's distribution network for that product. Barbe brings nearly 20 years experience in the medical device industry. Most recently, he served as Medtronic's director of sales for the spinal implant and image-guided surgery businesses in the international sector. Prior to Medtronic, Barbe worked for Baxter Healthcare in various roles, managing sales of Baxter's entire portfolio of hospital products via a direct sales organization and independent distributors. Scott R. Silverman, Chairman and Chief Executive Officer of VeriChip, commented, "Michael's wealth of relevant experience will be instrumental in helping us develop the market for VeriChip and the VeriMed Patient Identification System. I welcome him to the management team and look forward to Michael playing a key role in taking us to the next level." "I am extremely pleased to join VeriChip, a newly-public company," said Barbe. "I look forward to helping this emerging company grow its business, and helping to make VeriMed an essential medical product for at-risk patients." About VeriChip Corporation VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. VeriChip sells passive RFID systems for identification purposes and active RFID systems for local-area location and identification purposes. VeriChip recently began to market its VeriMed(TM) Patient Identification System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration. VeriChip Corporation is majority-owned by Applied Digital Inc. (NASDAQ:ADSX). For more information on VeriChip, please call 1-800-970-2447, or email . Additional information can be found online at http://www.verichipcorp.com/. Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Contact: VeriChip Corporation The Ruth Group Allison Tomek Nick Laudico (investors) 561-805-8000 (646) 536-7030 Jason Rando (media) (646) 536-7025 DATASOURCE: VeriChip Corporation CONTACT: VeriChip Corporation Allison Tomek 561-805-8000 The Ruth Group Nick Laudico (investors) (646) 536-7030 Jason Rando (media) (646) 536-7025 Web site: http://www.verichipcorp.com/

Copyright